Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in Myelofibrosis
NCT02871323Phase 1Withdrawn
- Sponsor
- Northwestern University
- Start
- Nov 2016
- Primary completion
- Nov 2016
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in myelofibrosis (MF), sponsored by Northwestern University. Primary endpoint: Incidence of Adverse Events up to 2 years. Planned start Nov 2016; status: withdrawn.
02
Drugs
durvalumab
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02871323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02871323.